A Trial in Mini-invasive Pilonidal Sinus Disease Surgery
Launched by HELSINKI UNIVERSITY CENTRAL HOSPITAL · Apr 30, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a multicenter study comparing two mini-invasive treatmnet options in pilonidal sinus disease. The study is carried out in four hospitals in Uusimaa county of Finland (Jorvi hospital, Porvoo hospital, Lohja hospital and Hyvinkää hospital). Patients, who are 18 or above, with a symptomatic primary pilonidal sinus disease are eligible for the study. On the day of surgery, the patient is randomly assigned to one of the two surgery groups. The main variable of our study is the healing rate at 2 months after surgery. Other variables to be studied are: postoperative complications, length o...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • primary pilonidal sinus disease
- • age 18 and above
- Exclusion Criteria:
- • recurrent pilonidal sinus disease
- • age under 18
- • inability to understand Finnish or Swedish (the questionnaires are in Finnish and Swedish only, the two official languages of Finland)
About Helsinki University Central Hospital
Helsinki University Central Hospital (HUCH) is a leading academic medical institution in Finland, dedicated to advancing healthcare through innovative research and clinical excellence. As a pivotal sponsor of clinical trials, HUCH integrates cutting-edge medical practices with rigorous scientific inquiry, fostering collaborations between researchers, healthcare professionals, and patients. The hospital is committed to enhancing patient outcomes and contributing to the global body of medical knowledge by conducting high-quality, ethically sound clinical studies across a diverse range of therapeutic areas. With a strong emphasis on education and training, HUCH plays a vital role in shaping the next generation of healthcare leaders and researchers.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsinki, , Finland
Patients applied
Trial Officials
Pauli Puolakkainen, Professor
Study Director
University of Helsinki, Department of Surgery
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported